158 related articles for article (PubMed ID: 16844539)
21. Absence of modulation of CD4+CD25 regulatory T cells in CTCL patients treated with bexarotene.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e95-102. PubMed ID: 19845755
[TBL] [Abstract][Full Text] [Related]
22. Endocrine side-effects of anti-cancer drugs: the impact of retinoids on the thyroid axis.
Graeppi-Dulac J; Vlaeminck-Guillem V; Perier-Muzet M; Dalle S; Orgiazzi J
Eur J Endocrinol; 2014 Jun; 170(6):R253-62. PubMed ID: 24616413
[TBL] [Abstract][Full Text] [Related]
23. Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides.
Pileri A; Delfino C; Grandi V; Pimpinelli N
Immunotherapy; 2013 Apr; 5(4):427-33. PubMed ID: 23557425
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
Kannangara AP; Levitan D; Fleischer AB
J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
[TBL] [Abstract][Full Text] [Related]
25. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Dummer R; Foss F; Dreno B; Bagot M
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
[TBL] [Abstract][Full Text] [Related]
26. Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
Querfeld C; Rosen ST; Guitart J; Rademaker A; Fung BB; Posten W; Kuzel TM
J Am Acad Dermatol; 2004 Jul; 51(1):25-32. PubMed ID: 15243520
[TBL] [Abstract][Full Text] [Related]
27. Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma.
Richardson SK; McGinnis KS; Shapiro M; Lehrer MS; Kim EJ; Vittorio CC; Junkins Hopkins JM; Rook AH
J Cutan Med Surg; 2003; 7(4 Suppl):8-12. PubMed ID: 12958701
[No Abstract] [Full Text] [Related]
28. Bexarotene reverses alopecia in cutaneous T-cell lymphoma.
Hanson M; Hill A; Duvic M
Br J Dermatol; 2003 Jul; 149(1):193-6. PubMed ID: 12890219
[No Abstract] [Full Text] [Related]
29. Pentostatin plus cyclophosphamide and bexarotene is an effective and safe combination in patients with mycosis fungoides/Sezary syndrome.
Calderon Cabrera C; de la Cruz Vicente F; Marín-Niebla A; Carrillo Cruz E; Rios Herranz E; Espigado Tocino I; Prats Martín C; Falantes JF; Martino Galiana ML; Perez-Simón JA
Br J Haematol; 2013 Jul; 162(1):130-2. PubMed ID: 23581433
[No Abstract] [Full Text] [Related]
30. Current treatment of Cutaneous T-Cell Lymphoma.
Duvic M
Dermatol Online J; 2001 Feb; 7(1):3. PubMed ID: 11328624
[TBL] [Abstract][Full Text] [Related]
31. Bexarotene monotherapy for epidermotropic CD8+ CTCL.
Kamstrup M; Gniadecki R
Dermatol Clin; 2008 Jan; 26 Suppl 1():45-7. PubMed ID: 18405187
[No Abstract] [Full Text] [Related]
32. Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization.
el-Azhary RA; Bouwhuis SA
Int J Dermatol; 2005 Jan; 44(1):25-8. PubMed ID: 15663654
[TBL] [Abstract][Full Text] [Related]
33. Treatment of mycosis fungoides with denileukin diftitox and oral bexarotene.
Talpur R; Duvic M
Clin Lymphoma Myeloma; 2006 May; 6(6):488-92. PubMed ID: 16796781
[TBL] [Abstract][Full Text] [Related]
34. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
35. [Mycosis fungoid treated with oral bexarotene: study of 13 cases].
Roche Gamón E; Pérez Ferriols A; Vilata Corell JJ; Alegre de Miquel V
Med Clin (Barc); 2007 Nov; 129(17):677. PubMed ID: 18005638
[No Abstract] [Full Text] [Related]
36. Folliculotropic mycosis fungoides responding to bexarotene gel.
Walling HW; Swick BL; Gerami P; Scupham RK
J Drugs Dermatol; 2008 Feb; 7(2):169-71. PubMed ID: 18335654
[TBL] [Abstract][Full Text] [Related]
37. [Bexarotene therapy in folliculotropic cutaneous T-cell lymphoma].
Drugeon C; Charlat I; Boulinguez S; Viraben R
Ann Dermatol Venereol; 2007; 134(8-9):639-43. PubMed ID: 17925686
[TBL] [Abstract][Full Text] [Related]
38. Development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome and review of the literature.
Sanli H; Akay BN; Ozcan M
J Drugs Dermatol; 2010 Aug; 9(8):1014-6. PubMed ID: 20684154
[TBL] [Abstract][Full Text] [Related]
39. [Diagnosis and treatment for cutaneous T-cell lymphomas].
Hamada T; Iwatsuki K
Nihon Rinsho; 2012 Apr; 70 Suppl 2():537-43. PubMed ID: 23134012
[No Abstract] [Full Text] [Related]
40. Targeted therapies for cutaneous T-cell lymphomas.
Kaplan JB; Guitart J; Giles FJ
Expert Rev Hematol; 2014 Aug; 7(4):481-93. PubMed ID: 25025372
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
